References
1.EMA. Biosimilars in the EU: Information guide for healthcare professionals. Available at: http://bit.ly/2qXnNpI. Accessed March 2018. 2.FDA. Vaccines, Blood & Biologics. Available at: http://bit.ly/2AYocKr. Accessed March 2018 3.Walsh, G. Nat Biotechnol 2014;32: 992–1000. 4.Morrow, T. Defining the difference: What Makes Biologics Unique. Biotechnology Healthcare. 2004;1(4):24-29. Available at: http://bit.ly/2D2hhAl. Accessed March 2018. 5.Medicines for Europe. Biosimilar Medicines Handbook. Available at: http://bit.ly/1QCnNMR. Accessed March 2018. 6.Apobiologix. Manufacturing. Available at: http://bit.ly/2ryyAUW . Accessed March 2018. 7.Schiestl M, et al. Nat Biotechnol 2011;29:310–2. 8.Weise M, et al. Blood 2012;120;5111–7. 9.EMA. Guideline on similar biological medicinal products. Available at: http://bit.ly/2ckWrzf. Accessed March 2018. 10.TGA. Evaluation of Biosimilars. Available from: http://bit.ly/2Fi58wT. Accessed March 2018. 11.FDA. Biosimilar and Interchangeable Products. Available at: http://bit.ly/2G1oVhv. Accessed March 2018. 12.12. WHO. Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs). Available at: http://bit.ly/2oU099B. Accessed March 2018. 13.FDA. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. Available at: http://bit.ly/2qySWih. Accessed March 2018. 14.EMA. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Available at: http://bit.ly/1IiuZfS. Accessed March 2018. 15.Brinks V, et al. Pharm Res 2011;28:386–93. 16.Ventola CL. PT 2013;38:270–287. 17.Gudat U. Pharma Horizon 2016;1:35–38. 18.Schneider C. Ann Rheum Dis. 2013;72:315–8. 19.Kurki P, et al. BioDrugs 2017. 20.IGBA. Biosimilar medicines — a commitment to scientific excellence. Available at http://bit.ly/2oOanKu. Accessed March 2018. 21.Aus. Govt. Department of Health. Biosimilar medicines: the basics for health care professionals. Available at: http://bit.ly/2D3vdtK. Accessed March 2018. 22.Bui et al (2015). Key considerations in the preclinical development of biosimilars. Drug Discovery Today 20(SI):3–15. 23.Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. (2003). 24.Interchangeability of Biosimilars: A European Perspective. Available from: http://bit.ly/2FuiiGj. Accessed March 2018. 25.Ebbers HC, et al. Expert Opin Biol Ther. 2012;12(11):1473–85. 26.Glintborg B, et al. Ann Rheum Dis 2017; [Epub ahead of print]. 27.McCamish M, Woollett G. Clin Pharmacol Ther 2013;93:315–7. 28.Chirino AJ, Mire-Sluis A. Nature Biotechnol 2004;22:1383–91